Eighteen months after its December 2024 FDA approval, Ryoncil generated $115 million in net revenue across its first full commercial year, with the fourth quarter alone contributing $36 million. That quarterly figure represents the fastest revenue cadence yet for remestemcel-L-rknd, and it arrives while Mesoblast is still operating exclusively in pediatric SR-aGvHD. The adult indication, a market the company estimates at three times the size of the pediatric population, has not yet contributed a single dollar to that total. That structural asymmetry shapes everything about how to read this launch.
The clinical pipeline activity running alongside the commercial ramp is where the real complexity sits. A registration trial for adult SR-aGvHD is now enrolling, with up to 40 U.S. sites expected to activate this year, collectively covering roughly 60 percent of the approximately 8,500 annual adult allogeneic bone marrow transplant recipients in the country. Separately, the first FDA-approved mesenchymal stromal cell therapy just cleared IND review for a direct-to-registrational study in ambulatory children aged 5 to 9 with Duchenne muscular dystrophy, a condition affecting approximately 15,000 children in the U.S. That IND clearance signals FDA willingness to let Mesoblast skip exploratory dose-finding and move straight to a pivotal design, which compresses development risk considerably.
The rexlemestrocel-L program adds another pressure point. Enrollment in the MSB-DR004 Phase 3 trial for chronic low back pain associated with degenerative disc disease has hit its target of at least 300 patients, who will now be followed to the 12-month primary endpoint measuring pain reduction versus placebo. Simultaneously, Mesoblast has received a BLA filing number and requested modular review for rexlemestrocel-L in a completely different indication: prevention of life-threatening gastrointestinal bleeding from right ventricular dysfunction in end-stage heart failure patients on left ventricular assist devices. Running two late-stage regulatory tracks for the same asset in parallel is unusual and operationally demanding, particularly with a reported cash position of $103 million after drawing down $50 million to retire maturing debt. Net operating cash spend for the full year was $43.8 million, with the second half burning only $13.4 million, suggesting tightening discipline.
The single number to track now is Q1 FY2027 Ryoncil revenue. If momentum from the $36 million Q4 figure holds or accelerates as the adult SR-aGvHD trial sites activate and the commercial infrastructure matures, it validates the thesis that pediatric penetration was merely the floor. A plateau would expose how much of the revenue story depends on label expansion still in clinical-stage risk.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
